Anti-ARF1 [ARFS 3F1]
ARF1 is a member of the ARF family of small G proteins and is a component of Golgi-derived non-clathrin coated vesicles.
Contributors
| Inventor | Institute |
|---|---|
| Sharon Tooze | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151249 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell signaling and signal transduction |
| Application: | ELISA ; IHC ; IF ; WB |
| Target: | ADP-Ribosylation Factor 1 (ARF1) |
| Reactivity: | Human |
| Clone: | ARFS 3F1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | ARF1 is a member of the ARF family of small G proteins and is a component of Golgi-derived non-clathrin coated vesicles. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Immunogen: | C-terminal Human ARF1 peptide SNQLRNQ |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | ARF1 is a member of the ARF family of small G proteins and is a component of Golgi-derived non-clathrin coated vesicles. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Lim et al. 2010. Genes Dev. 24(14):1496-506. PMID: 20634316. The CNK1 scaffold binds cytohesins and promotes insulin pathway signaling. Yano et al. 2008. Mol Biol Cell. 19(3):822-32. PMID: 18094045. Fbx8 makes Arf6 refractory to function via ubiquitination. Cotton et al. 2007. Mol Biol Cell. 18(2):501-11. PMID: 17122362. Endogenous ARF6 interacts with Rac1 upon angiotensin II stimulation to regulate membrane ruffling and cell migration. Austin et al. 2000. J Biol Chem. 275(29):21862-9. PMID: 10807927. Direct and GTP-dependent interaction of ADP-ribosylation factor 1 with clathrin adaptor protein AP-1 on immature secretory granules. |
|---|
Images
View Gallery
Product Images
99f6d722-2cd4-4503-9f3e-0b782390e861.png
Effect of CXCL12 on Arf1 activity. CLL cells were incubated in the presence or absence of CXCL12 and assayed for Arf1 GTP loading. CXCL12 treatment increased Arf1-GTP loading in chemokine-responsive CLL samples (n = 6) but not in nonresponsive samples. Adapted from Derek et al; J Immunol August 1; 2013; 191 (3) 1496-1504
Related Tools for Antibodies
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
